34 results about "Myotonia" patented technology

The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav1.7, a preparation method thereof and the use thereof. A compound represented by formula 1 according to the invention, or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof may be effectively used for the prevention or treatment of pain, for example, acute pain, chronic pain, neuropathic pain, post-surgery pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, or paroxysmal extreme pain disorder (PEPD).

Methods and compositions for treating myotonia and dystrophies.

The invention relates to a separated nucleic acid of encoded skeletal muscle chloride ion channel mutants, an isolated polypeptide, a method for screening a myotonia congenital disease susceptible biological sample, a system for screening a myotonia congenital disease susceptible biological sample and a kit for screening a myotonia congenital disease susceptible biological sample. Specifically, the separated nucleic acid of encoded skeletal muscle chloride ion channel mutants, compared with the SEQ ID NO:1, has at least one mutation selected from the following: c.2655_2656insC, c.1616C>T, c.2057_2058delAC and c.313C>T. By detecting the existence of the new mutants in the biological sample, whether the biological sample is susceptible to a myotonia congenital disease can be effectively detected.

Condensed pyridine compounds represented by formula (I): wherein: R<1 >and R<3 >are, independently, hydrogen, halogen, lower alkyl, or lower alkoxy; R<2 >represents an amino substituent; ring A is a benzene ring, pyridine ring, thiophene ring, or furan ring; and B represents a substituent containing a ring structure. Also, pharmaceutically acceptable salt and hydrates thereof. These compounds are clinically useful medicaments having serotonin antagonism, and in particular, for treating, ameliorating, or preventing spastic paralysis. They are also useful as central muscle relaxants for ameliorating myotonia.

The invention discloses a writing system for a Parkinson's disease patient. The writing system comprises a control component. The control component comprises a control cavity. The control cavity is internally provided with a control device. The control device comprises a power supply module, an image identification module, a driving module, a buzzer, a gyroscope and a control module, wherein the power supply module is used for supplying power; the image identification module is used for identifying images collected by a camera; the driving module is used for supplying power to a coil A and a coil B; the buzzer is used for giving a sound alarm; the gyroscope is used for acquiring the accelerated speed of the control device; and the control module is used for controlling the driving module to work according to image information acquired by the image identification module and accelerated speed information acquired by the gyroscope. By means of the writing system, static tremor and myotonia of the Parkinson's disease can be dealt with at the same time; the Parkinson's disease patient can complete writing completely and coherently with the writing system in hand; and the requirement ofthe patient is met.